Ironwood Pharmaceuticals Long Term Debt 2010-2025 | IRWD

Ironwood Pharmaceuticals long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.
Ironwood Pharmaceuticals Annual Long Term Debt
(Millions of US $)
2024 $584
2023 $498
2022 $396
2021 $0
2020 $430
2019 $408
2018 $366
2017 $396
2016 $367
2015 $354
2014 $161
2013 $178
2012 $0
2011 $0
2010 $0
2009 $1
Ironwood Pharmaceuticals Quarterly Long Term Debt
(Millions of US $)
2025-03-31 $584
2024-12-31 $584
2024-09-30 $599
2024-06-30 $624
2024-03-31 $473
2023-12-31 $498
2023-09-30 $523
2023-06-30 $598
2023-03-31
2022-12-31 $396
2022-09-30 $396
2022-06-30 $395
2022-03-31 $395
2021-12-31
2021-09-30 $333
2021-06-30 $329
2021-03-31 $436
2020-12-31 $430
2020-09-30 $425
2020-06-30 $419
2020-03-31 $426
2019-12-31 $408
2019-09-30 $403
2019-06-30 $353
2019-03-31 $360
2018-12-31 $366
2018-09-30 $370
2018-06-30 $380
2018-03-31 $388
2017-12-31 $396
2017-09-30 $392
2017-06-30 $388
2017-03-31 $384
2016-12-31 $367
2016-09-30 $363
2016-06-30 $339
2016-03-31 $349
2015-12-31 $354
2015-09-30 $360
2015-06-30 $364
2015-03-31 $160
2014-12-31 $161
2014-09-30 $168
2014-06-30 $171
2014-03-31 $173
2013-12-31 $178
2013-09-30 $178
2013-06-30 $175
2013-03-31 $175
2012-12-31 $0
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $1
2011-03-31 $1
2010-12-31 $0
2010-09-30 $0
2010-06-30 $2
2010-03-31 $2
2009-12-31 $1
2009-09-30 $2
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.132B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $81.321B 31.28
Zoetis (ZTS) United States $67.725B 25.27
Daiichi Sankyo, - (DSNKY) Japan $46.412B 23.79
Takeda Pharmaceutical (TAK) Japan $46.074B 9.16
BeOne Medicines - (ONC) Cayman Islands $31.945B 0.00
Sandoz Group AG (SDZNY) Switzerland $26.145B 0.00
Summit Therapeutics (SMMT) United States $21.292B 0.00
Merck (MKKGY) Germany $17.234B 12.63
Shionogi (SGIOY) Japan $14.649B 0.00
United Therapeutics (UTHR) United States $13.735B 12.15
Neurocrine Biosciences (NBIX) United States $13.077B 44.79
Orion OYJ (ORINY) Finland $11.714B 28.23
IPSEN (IPSEY) France $10.870B 0.00
Stevanato Group S.p.A (STVN) Italy $8.028B 49.09
Corcept Therapeutics (CORT) United States $7.242B 58.87
Grifols, S.A (GRFS) Spain $6.944B 0.00
Ionis Pharmaceuticals (IONS) United States $6.724B 0.00
Madrigal Pharmaceuticals (MDGL) United States $6.625B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.204B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.214B 15.86
Soleno Therapeutics (SLNO) United States $4.358B 0.00
Hypermarcas (HYPMY) Brazil $2.945B 19.38
Crinetics Pharmaceuticals (CRNX) United States $2.902B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.650B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.558B 8.96
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.526B 13.66
Centessa Pharmaceuticals (CNTA) United Kingdom $2.059B 0.00
Ocular Therapeutix (OCUL) United States $1.945B 0.00
Endo (NDOI) United States $1.812B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.789B 0.00
ARS Pharmaceuticals (SPRY) United States $1.755B 0.00
Evotec AG (EVO) Germany $1.513B 0.00
Harrow (HROW) United States $1.328B 0.00
Guardian Pharmacy Services (GRDN) United States $1.301B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.206B 24.14
Dyne Therapeutics (DYN) United States $1.131B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.067B 0.00
Enliven Therapeutics (ELVN) United States $1.040B 0.00
Ardelyx (ARDX) United States $1.026B 0.00
Collegium Pharmaceutical (COLL) United States $1.021B 5.51
Verve Therapeutics (VERV) United States $0.992B 0.00
ProKidney (PROK) United States $0.963B 0.00
Akebia Therapeutics (AKBA) United States $0.935B 0.00
Cronos Group (CRON) Canada $0.791B 0.00
Xeris Biopharma Holdings (XERS) United States $0.785B 0.00
KalVista Pharmaceuticals (KALV) United States $0.728B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.727B 0.00
Xencor (XNCR) United States $0.658B 0.00
Relay Therapeutics (RLAY) United States $0.641B 0.00
Organogenesis (ORGO) United States $0.638B 0.00
Zevra Therapeutics (ZVRA) United States $0.614B 0.00
USANA Health Sciences (USNA) United States $0.595B 11.97
Elite Pharmaceuticals (ELTP) United States $0.591B 0.00
Theravance Biopharma (TBPH) United States $0.552B 0.00
Bioventus (BVS) United States $0.540B 13.69
Oruka Therapeutics (ORKA) United States $0.534B 0.00
Siga Technologies (SIGA) United States $0.510B 10.66
Tourmaline Bio (TRML) United States $0.508B 0.00
Savara (SVRA) United States $0.446B 0.00
Aquestive Therapeutics (AQST) United States $0.412B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.366B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.360B 9.74
AleAnna (ANNA) United States $0.332B 0.00
Altimmune (ALT) United States $0.331B 0.00
Nanobiotix S.A (NBTX) France $0.321B 0.00
Nektar Therapeutics (NKTR) United States $0.310B 0.00
Aldeyra Therapeutics (ALDX) United States $0.310B 0.00
Esperion Therapeutics (ESPR) United States $0.299B 0.00
Heron Therapeutics (HRTX) United States $0.291B 0.00
Nature's Sunshine Products (NATR) United States $0.272B 24.93
OmniAb (OABI) United States $0.256B 0.00
Larimar Therapeutics (LRMR) United States $0.248B 0.00
Liminatus Pharma (LIMN) United States $0.227B 0.00
MediWound (MDWD) Israel $0.220B 0.00
4D Molecular Therapeutics (FDMT) United States $0.212B 0.00
China SXT Pharmaceuticals (SXTC) China $0.184B 0.00
Galectin Therapeutics (GALT) United States $0.184B 0.00
Aclaris Therapeutics (ACRS) United States $0.184B 0.00
Lyell Immunopharma (LYEL) United States $0.184B 0.00
Journey Medical (DERM) United States $0.177B 0.00
Profound Medical (PROF) Canada $0.171B 0.00
Avita Medical (RCEL) United States $0.153B 0.00
Korro Bio (KRRO) United States $0.150B 0.00
Lexeo Therapeutics (LXEO) United States $0.137B 0.00
Inhibikase Therapeutics (IKT) United States $0.132B 0.00
Protara Therapeutics (TARA) United States $0.128B 0.00
Cardiol Therapeutics (CRDL) Canada $0.119B 0.00
Cassava Sciences (SAVA) United States $0.114B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.113B 0.00
Innate Pharma SA (IPHYF) France $0.110B 0.00
Vivani Medical (VANI) United States $0.095B 0.00
Nutriband (NTRB) United States $0.095B 0.00
Fractyl Health (GUTS) United States $0.094B 0.00
Achieve Life Sciences (ACHV) Canada $0.093B 0.00
VAXART, INC (VXRT) United States $0.092B 0.00
Metagenomi (MGX) United States $0.091B 0.00
Champions Oncology (CSBR) United States $0.086B 19.50
ESSA Pharma (EPIX) Canada $0.083B 0.00
Arch Biopartners (ACHFF) Canada $0.078B 0.00
Pyxis Oncology (PYXS) United States $0.077B 0.00
Surrozen (SRZN) United States $0.077B 0.00
Inotiv (NOTV) United States $0.076B 0.00
Context Therapeutics (CNTX) United States $0.075B 0.00
Dominari Holdings (DOMH) United States $0.075B 0.00
Rafael Holdings (RFL) United States $0.074B 0.00
PMV Pharmaceuticals (PMVP) United States $0.073B 0.00
Avalo Therapeutics (AVTX) United States $0.072B 0.00
Wellgistics Health (WGRX) United States $0.071B 0.00
Assertio Holdings (ASRT) United States $0.071B 0.00
Telomir Pharmaceuticals (TELO) United States $0.065B 0.00
Unicycive Therapeutics (UNCY) United States $0.062B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.061B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
ElectroCore (ECOR) United States $0.058B 0.00
Klotho Neurosciences (KLTO) United States $0.057B 0.00
Century Therapeutics (IPSC) United States $0.054B 0.00
Jupiter Neurosciences (JUNS) United States $0.054B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.053B 39.06
Prelude Therapeutics (PRLD) United States $0.053B 0.00
NRx Pharmaceuticals (NRXP) United States $0.052B 0.00
Gain Therapeutics (GANX) United States $0.051B 0.00
Acrivon Therapeutics (ACRV) United States $0.045B 0.00
Mural Oncology (MURA) Ireland $0.042B 0.00
Karyopharm Therapeutics (KPTI) United States $0.038B 0.00
PolyPid (PYPD) Israel $0.038B 0.00
Iterum Therapeutics (ITRM) Ireland $0.032B 0.00
Plus Therapeutics (PSTV) United States $0.032B 0.00
Incannex Healthcare (IXHL) Australia $0.031B 0.00
Vivos Therapeutics (VVOS) United States $0.031B 0.00
FibroGen (FGEN) United States $0.030B 0.00
Tempest Therapeutics (TPST) United States $0.029B 0.00
SCYNEXIS (SCYX) United States $0.028B 0.00
Enlivex Therapeutics (ENLV) Israel $0.027B 0.00
Scienture Holdings (SCNX) United States $0.026B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.023B 0.00
Natural Alternatives (NAII) United States $0.022B 0.00
VYNE Therapeutics (VYNE) United States $0.022B 0.00
Relmada Therapeutics (RLMD) United States $0.021B 0.00
Cosmos Health (COSM) United States $0.020B 0.00
ProPhase Labs (PRPH) United States $0.019B 0.00
Lipocine (LPCN) United States $0.018B 0.00
CASI Pharmaceuticals (CASI) China $0.018B 0.00
BioLineRx (BLRX) Israel $0.018B 0.00
Citius Pharmaceuticals (CTXR) United States $0.018B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.018B 0.00
DURECT (DRRX) United States $0.018B 0.00
Carisma Therapeutics (CARM) United States $0.016B 0.00
Mannatech (MTEX) United States $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.015B 2.60
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
BioVie (BIVI) United States $0.014B 0.00
TherapeuticsMD (TXMD) United States $0.014B 0.00
Phio Pharmaceuticals (PHIO) United States $0.013B 0.00
Ainos (AIMD) United States $0.011B 0.00
Lyra Therapeutics (LYRA) United States $0.011B 0.00
Biomerica (BMRA) United States $0.010B 0.00
TransCode Therapeutics (RNAZ) United States $0.010B 0.00
Aptorum Group (APM) United Kingdom $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Mangoceuticals (MGRX) United States $0.009B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Talphera (TLPH) United States $0.009B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.005B 0.00
Qualigen Therapeutics (QLGN) United States $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
SciSparc (SPRC) Israel $0.004B 0.00
SHINECO (SISI) China $0.004B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
PainReform (PRFX) Israel $0.003B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Conduit Pharmaceuticals (CDT) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
Indivior (INDV) United States $0.000B 10.02
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00